Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbix Biosystms ( (TSE:MBX) ) has shared an announcement.
Microbix Biosystems reported first-quarter fiscal 2026 revenue of $4.2 million, up 13% from the prior quarter but 30% below the same period last year, reflecting ongoing recovery after setbacks with two major clients in 2025. The quarter was marked by sharply lower antigen sales into China, partially offset by rising sales of branded QAPs products, resulting in a 41% gross margin and a controlled net loss of $1.17 million.
Management emphasized that the revenue and loss levels were in line with its 2026 budget and highlighted a strong balance sheet, including a current ratio of 7.51 and modest leverage with a 0.38 debt-to-equity ratio. The company is aggressively pursuing new client programs and expanding its product portfolio to restore sales above breakeven, improve margins, and create long-term shareholder value in both its diagnostics business and its Kinlytic urokinase drug program.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that creates proprietary biological products for human health, employing over 120 staff and generating C$18.6 million in revenue in fiscal 2025. It supplies critical antigens for immunoassays and laboratory quality assessment products such as QAPs and QUANTDx, serving diagnostics makers and clinical laboratories worldwide.
Average Trading Volume: 70,437
Technical Sentiment Signal: Sell
Current Market Cap: C$31.87M
For an in-depth examination of MBX stock, go to TipRanks’ Overview page.